Payment overview · 2025
General Payments
$16.27
1 reported records · 1 companies
Healthcare provider profile · identity verified
Fassil W Gemechu, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · CLEVELAND, OH · NPI 1598776072
Verified facts
What the public records show
CMS Open Payments records show Fassil W Gemechu, MD received $16.27 in general payments during 2025 across 1 reported records.
Astellas Pharma US Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.27 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1060 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 649 | 149 |
| Gabapentin | Gabapentin | 554 | 75 |
| Lisinopril | Lisinopril | 476 | 120 |
| Xarelto | Rivaroxaban | 372 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 370 | 57 |
| Eliquis | Apixaban | 369 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 75 |
| Omeprazole | Omeprazole | 351 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 63 |
| Sertraline Hcl | Sertraline Hcl | 307 | 60 |
| Potassium Chloride | Potassium Chloride | 296 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 79 |
| Losartan Potassium | Losartan Potassium | 282 | 72 |
| Furosemide | Furosemide | 249 | 61 |
| Metformin Hcl | Metformin Hcl | 224 | 58 |
| Trazodone Hcl | Trazodone Hcl | 215 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 209 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 52 |
| Carvedilol | Carvedilol | 174 | 32 |
| Jardiance | Empagliflozin | 166 | 14 |
| Mirtazapine | Mirtazapine | 142 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 139 | 32 |
| Januvia | Sitagliptin Phosphate | 134 | 17 |
| Tramadol Hcl | Tramadol Hcl | 128 | 19 |
| Montelukast Sodium | Montelukast Sodium | 122 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 36 |
| Simvastatin | Simvastatin | 116 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 46 |
| Metformin Hcl Er | Metformin Hcl | 106 | 29 |
| Tradjenta | Linagliptin | 101 | 12 |
| Nystatin | Nystatin | 100 | 30 |
| Levetiracetam | Levetiracetam | 99 | 15 |
| Divalproex Sodium | Divalproex Sodium | 95 | 13 |
| Allopurinol | Allopurinol | 90 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 88 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 83 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 80 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 79 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 17 |
| Jantoven | Warfarin Sodium | 78 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 21 |
| Entresto | Sacubitril/Valsartan | 76 | suppressed |
| Baclofen | Baclofen | 70 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 38 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Famotidine | Famotidine | 67 | 21 |
| Memantine Hcl | Memantine Hcl | 67 | suppressed |
| Spironolactone | Spironolactone | 65 | 20 |
| Sucralfate | Sucralfate | 63 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 13 |
| Finasteride | Finasteride | 57 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 15 |
| Glipizide | Glipizide | 56 | 18 |
| Lokelma | Sodium Zirconium Cyclosilicate | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Alprazolam | Alprazolam | 52 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 52 | suppressed |
| Tivicay | Dolutegravir Sodium | 52 | suppressed |
| Atenolol | Atenolol | 51 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 49 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 16 |
| Glimepiride | Glimepiride | 47 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Methadone Hcl | Methadone Hcl | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 12 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 44 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Humalog | Insulin Lispro | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Torsemide | Torsemide | 42 | 16 |
| Sodium Chloride | Sodium Chloride Irrig Solution | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 11 |
| Valsartan | Valsartan | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 19 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Prednisone | Prednisone | 29 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Cephalexin | Cephalexin | 28 | 17 |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 11 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Meropenem | Meropenem | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Admelog | Insulin Lispro | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 13 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 14 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.27 · 1 records | Astellas Pharma US Inc | Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error